Basit öğe kaydını göster

dc.contributor.advisorCan, Filiz
dc.contributor.authorÇakır, Fatma Fulden
dc.date.accessioned2019-04-12T12:36:15Z
dc.date.issued2019-04-12
dc.date.submitted2019-03-26
dc.identifier.citation1. 2017 REPORT Global Initiative for Chronic Obstructive Lung (GOLD) Internet. 2017Erişim Tarihi:14 Eylül 2018. Erişim adresi: http:www.goldcopd.com 2. Chacon PFS, Schon CF, Furtado VHLA, Signoretti GLAM, Oliveira JPP, Ribeiro AG, et al. Support and rehabilitation of patients with pulmonary expansion deficit by using game therapy. Annu Int.Conf.2016:5632–5. 3. Coventry PA, Bower P, Keyworth C, Kenning C, Knopp J, Garrett C, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One. 2013;8(4):e60532. 4. Leidy NK, Murray LT, Monz BU, Nelsen L, Goldman M, Jones PW, et al. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014 Oct;15:124. 5. Liu X-L, Tan J-Y, Wang T, Zhang Q, Zhang M, Yao L-Q, et al. Effectiveness of home-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Rehabil Nurs. 2014;39(1):36–59. 6. Weldam SWM, Lammers J-WJ, Decates RL, Schuurmans MJ. Daily activities and health-related quality of life in patients with chronic obstructive pulmonary disease: psychological determinants: a cross-sectional study. Health Qual Life Outcomes. 2013 Nov;11:190. 7. Sciriha A, Lungaro-Mifsud S, Scerri J, Magro R, Camilleri L, Montefort S. Health status of COPD patients undergoing pulmonary rehabilitation: A comparative responsiveness of the CAT and SGRQ. Chron Respir Dis. 2017;14(4):352–9. 8. Pitta F, Troosters T, Probst VS, Langer D, Decramer M, Gosselink R. Are patients with COPD more active after pulmonary rehabilitation? Chest. 2008 Aug;134(2):273–80. 9. Yavuz Selim İntepe, Eylem Yıldırım, Bayram Metin, Seyhan Karaçavuş, Özlem Balbaloğlu. The Evaluation of Bone Mineral Density in Patients with Chronic Obstructive Pulmonary Disease. Bozok Medilcal J. 2015;1(1):20–6. 10. Man WD-C, Kemp P, Moxham J, Polkey MI. Exercise and muscle dysfunction in COPD: implications for pulmonary rehabilitation. Clin Sci (Lond). 2009;117(8):281–91. 11. Celli B, Goldstein R, Knobil K. Future perspectives in COPD. 2005Dec;p.41-8. 12. Larson T, Gudavalli R, Prater D, Sutton S. Critical analysis of common canister programs: a review of cross-functional considerations and health system economics. Curr Med Res Opin. 2015 Apr;31(4):853–60. 13. Islam SMS, Purnat TD, Phuong NTA, Mwingira U, Schacht K, Froschl G. Non-communicable diseases (NCDs) in developing countries: a symposium report. Vol. 10, Globalization and health. England; 2014. p. 81. 14. Kart L, Akkoyunlu M.E, Bayram M, Yakar F, Kutbay Özçelik H, Karaköse F, et al. COPD: an underdiagnosed disease at hospital environment. Wien Klin Wochenschr. 2014 Feb;126(3–4):73–8. 15. Ghattas C, Dai A, Gemmel DJ, Awad MH. Over diagnosis of chronic obstructive pulmonary disease in an underserved patient population. Int J Chron Obstruct Pulmon Dis. 2013;8:545–9. 16. Abul Y,Özlü T,Türkiyede KOAH epidemiyolojisi,Karadeniz Teknik Üniversitesi Göğüs hastalıkları Anabilim Dalı,Trabzon 2013;1(1):7 17. Arslan Z, Ilgazli A, Etiler N, Hamzaoglu O. Prevalence of chronic obstructive pulmonary disease in kocaeli: an industrialised city in Turkey. Balkan Med J. 2013 Dec;30(4):387–93. 18. Perez-Padilla R, Fernandez R, Lopez Varela MV, Montes de Oca M, Muino A, Talamo C, et al. Airflow obstruction in never smokers in five Latin American cities: the PLATINO study. Arch Med Res. 2012 Feb;43(2):159–65. 20. Guirguis-Blake JM, Senger CA, Webber EM, Mularski R, Whitlock EP. Screening for Chronic Obstructive Pulmonary Disease: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD); 2016. 21. Kalfopoulos M, Wetmore K, K ElMallah M. Pathophysiology of Alpha-1 Antitrypsin Lung Disease. Methods Mol Biol. 2017;1639:9–19. 22. Karl FM, Holle R, Bals R, Greulich T, Jorres RA, Karch A, et al. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res. 2017 Apr;18(1):60. 23. Rajkumar P, Pattabi K, Vadivoo S, Bhome A, Brashier B, Bhattacharya P, et al. A cross-sectional study on prevalence of chronic obstructive pulmonary disease (COPD) in India: rationale and methods. BMJ Open. 2017 May;7(5):e015211. 24. Edwards SC, Fairbrother SE, Scowcroft A, Chiu G, Ternouth A, Lipworth BJ. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK. Int J Chron Obstruct Pulmon Dis. 2016;11:2851–8. 25. Murray CJL, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013 Aug;310(6):591–608. 26. Murray CJL, Richards MA, Newton JN, Fenton KA, Anderson HR, Atkinson C, et al. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet (London, England). 2013 Mar;381(9871):997–1020. 27. Qaseem A, Wilt TJ ve diğerleri. (2011). Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society and European Respiratory Society. Ann Intern Med, 155, 179- 191 28. Grone O, Garcia-Barbero M. Integrated care: a position paper of the WHO European Office for Integrated Health Care Services. Int J Integr Care. 2001;1:e21. 29. Rajput C. Chronic Obstructive Pulmonary Disease Meta Genome-Wide Association Studies. New Insights into the Genetics of Chronic Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol. 2017 Jul;57(1):1–2. 30. Wain L V, Shrine N, Artigas MS, Erzurumluoglu AM, Noyvert B, Bossini-Castillo L, et al. Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nat Genet. 2017 Mar;49(3):416–25. 31. Milanzi EB, Brunekreef B, Koppelman GH, Wijga AH, van Rossem L, Vonk JM, et al. Lifetime secondhand smoke exposure and childhood and adolescent asthma: findings from the PIAMA cohort. Environ Health. 2017 Feb;16(1):14. 32. Fontana L, Lee S-J, Capitanelli I, Re A, Maniscalco M, Mauriello MC, et al. Chronic Obstructive Pulmonary Disease in Farmers: A Systematic Review. J Occup Environ Med. 2017 Aug;59(8):775–88. 33. Sadhra S, Kurmi OP, Sadhra SS, Lam KBH, Ayres JG. Occupational COPD and job exposure matrices: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:725–34. 34. Mannino, D.M.,Buist, A.S. (2007) Global burden of COPD: risk factors, prevalence, and future trends. Lancet, 370 (9589), 765-773. 35. Mannino, D.M.,Davis, K.J. (2006). Lung function decline and outcomes in an elderly population. Thorax, 61 (6), 472-477. 36. Leung JM, Tiew PY, Mac Aogain M, Budden KF, Yong VFL, Thomas SS, et al. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respirology. 2017 May;22(4):634–50. 37. Grigsby M, Siddharthan T, Chowdhury MA, Siddiquee A, Rubinstein A, Sobrino E, et al. Socioeconomic status and COPD among low- and middle-income countries. Int J Chron Obstruct Pulmon Dis. 2016;11:2497–507. 38. Mahmood T, Singh RK, Kant S, Shukla A Das, Chandra A, Srivastava RK. Prevalence and etiological profile of chronic obstructive pulmonary disease in nonsmokers. Lung India. 2017;34(2):122–6. 39. Park HJ, Byun MK, Kim HJ, Kim JY, Kim Y-I, Yoo K-H, et al. Dietary vitamin C intake protects against COPD: the Korea National Health and Nutrition Examination Survey in 2012. Int J Chron Obstruct Pulmon Dis. 2016;11:2721–8. 40. Mekary RA. A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women. Evid Based Med. 2016 Feb;21(1):36. 41. Casanova C, Oca MM De, Mendez RA, Plata VP, Cabral HJ, Ph D. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. 2004;1005–12. 42. Başyiğit İ. (2010). KOAH Patogenezi ve Fizyopatolojisi. Toraks Cerrahisi Bülteni. 1(2), 114- 118. 43. 2014 Global Initiative for Chronic Obstructive Lung (GOLD), ). the Global Strategy For The Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Internet. 2014Erişim Tarihi:10 Eylül 2018. Erişim adresi: http:www.goldcopd.com 44. Raherison, C.,Girodet, P.O. (2009). Epidemiology of COPD. European Respiratory Review; 18 (114), 213-221. 45. MacNee, Pathogenesis of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society; 2 (4), 258-266 46. Eapen MS, Myers S, Walters EH, Sohal SS. Airway inflammation in chronic obstructive pulmonary disease (COPD): a true paradox. Expert Rev Respir Med. 2017 Aug;1–13. 47. DeTurk W.E., Cahalin, L.P. (2004). Cardiovasculary and Pulmonary Physical Therapy. Newyork::GTS 48. MacNee, W. (2005). Pathogenesis of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society, 2 (4), 258-266; discussion 290-251. 49. Antoniu SA. Descriptors of dyspnea in obstructive lung diseases. Vol. 5, Multidisciplinary Respiratory Medicine. 2010. p. 216–9. 50. Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med. 2009 Mar;360(13):1329–35. 51. Gülbay BE, Saryal SB, Acıcan T. (2003). Patogenez ve inflamasyon. Kronik Obstruktif Akciğer Hastalığı. Ankara Bilimsel Tıp Yayınevi. B2, 21- 33 52. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013 Oct;188(8):e13- 53. Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. 2006;61–7. 54. Ho C-F, Maa S-H. [Application of the 6-Minute Walking Test and Shuttle Walking Test in the Exercise Tests of Patients With COPD]. Hu Li Za Zhi. 2016 Aug;63(4):107–15. 55. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319–38. 56. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948–68. 57. Fahndrich S, Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, et al. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency. Respir Med. 2017 Aug;129:8–15. 58. Kim K, Byun M, Lee W, Cynn H, Kwon O, Yi C. Effects of breathing maneuver and sitting posture on muscle activity in inspiratory accessory muscles in patients with chronic obstructive pulmonary disease. Vol. 7, Multidisciplinary Respiratory Medicine. 2012. p. 9. 59. Gonçalves MA, Francisco DS, Medeiros CS, Brüggemann AK,Mazo GZ, Paulin E, Postural alignment of patients with chronic obstruktive pulmonary disease,Fisioter.mov.vol.30, no.3 Crutiba,2017 60. Mador MJ, Kufel TJ. Reproducibility of visual analog scale measurements of dyspnea in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992 Jul;146(1):82–7. 61. Nishiyama O, Taniguchi H, Kondoh Y, Nishimura K, Suzuki R, Takagi K, et al. The effectiveness of the visual analogue scale 8 in measuring health-related quality of life for COPD patients. Respir Med. 2000 Dec;94(12):1192–9. 62. Dajczman E,Wardini R,Kasymjanova G, Prefontaine D, Baltzan MA,Wolkove N,Six minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation,Can Respir J.,2015Jul;22(4) 225-229. 63. Spruit MA, Burtin C, Boever P, Langer D,Vogiatzis I, Wouters E ve ark. COPD and exercise:does it make a difference,Breathe She.,2016 Jun;12(2)38-49. 64. Gökbel H, Kronik akciğer hastalığı ve egzersiz,Selçuk Üniversitesi Tıp Fakültesi,Konya,Türkiye Klinikleri J Sport Med-Special Topics.2015;1(2):15-9. 65. Kim K, Byun M, Lee W, Cynn H, Kwon O, Yi C. Effects of breathing maneuver and sitting posture on muscle activity in inspiratory accessory muscles in patients with chronic obstructive pulmonary disease. Vol. 7, Multidisciplinary Respiratory Medicine. 2012. p. 9. 66. Bestall JC, Paul EA, Garrod R.(1999).Usefulness of Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease.Thorax,54;581-86. 67. Mahler DA, Criner GJ. (2007). Assesment tools for chronic obstructive pulmonary disease. Do never metrics allow for disease modification? Proc Am Thorac Soc, 4, 507- 511. 68. Dodd JW, Hogg L, Nolan J, Jefford H, Grant A, Lord VM, et al. The COPD assessment test (CAT): Response to pulmonary rehabilitation. A multicentre, prospective study. Thorax. 2011;66(5):425–9. 69. Yorgancıoğlu A, Polatlı M, Aydemir Ö, Demirci N, Kırkıl G, Naycıatış G. Ve ark.,KOAH değerlendirme testinin Türkçe geçerlilik ve güvenilirliği. Tuberk Toraks. 2012;60(4):314–20. 70. Jones PW, Quirk FH, Baveystock CM. (1991). The St Georges Respiratory Questionnaire. Respiratory medicine, 85(B), 25- 31 71. Polatlı M, Yorgancıoğlu A, Aydemir Ö, Yılmaz Demirci N, Kırkıl G, Atış Naycı S, et al. Validity and reliability of Turkish version of St. George’s respiratory questionnaire. Tuberk Toraks [Internet]. Erişim tarihi: 2013;61(2):81–7. 72. Celli B, Tetzlaff K, Criner G, Polkey MI, Sciurba F, Casaburi R, et al. The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med [Internet]. 2016 Dec 15;194(12):1483–93. 73. Press VG, Cifu AS, White SR. Screening for Chronic Obstructive Pulmonary Disease. JAMA. 2017 Nov;318(17):1702–3. 74. Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald VM, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med J Aust. 2017 Nov;207(10):436–42. 75. Ho C-F, Maa S-H. [Application of the 6-Minute Walking Test and Shuttle Walking Test in the Exercise Tests of Patients With COPD]. Hu Li Za Zhi. 2016 Aug;63(4):107–15. 76. RW L, EG M. Certain aspects of infantile paralysis: With a description of a method of muscle testing. J Am Med Assoc [Internet]. 1916 Mar 4;LXVI(10):729–33. Available from: http://dx.doi.org/10.1001/jama.1916.02580360031009 77. Bandy WBNRW. Chapter 1. Measurement of Range of Motion and Muscle Length: Background, History and Basic Principles. In: Joint Range of Motion and Muscle Length Testing. 1st ed. 9781416068709; 2002. 78. Tobergte DR, Curtis S. Beck’S Depression Inventory. J Chem Inf Model. 2013;53(9):1689–99. 79. Tuğlu C.,Aktürk Z, Dağdeviren N, Türe M, Birinci Basamak İçi̇n Beck Depresyon Tarama Ölçeği̇ni̇n Türçe Çevi̇ri̇mi̇ni̇n Geçerli̇k Güveni̇rli̇ği̇. Türk Ai̇le Heki̇mli̇ği Dergi̇si̇. 2005;9(3):117–22. 80. Seber G, Dilbaz N, Kaptanoğlu C, Tekin D. Umutsuzluk Ölçeği: Geçerlilik ve Güvenirliği. Kriz Derg [Internet]. 1998;1(3):139–42. 81. Kucukdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum. 2004 Feb;51(1):14–9. 82. R. P. Sağlık araştırmalarında yeni bir kavram: Yaşam kalitesi, bir yaşam kalitesi ölçeğinin kronik hastalarda geçerlik ve güvenirliğinin sınanması. Hemşirelik Bülteni. 1995;(9):85–95. 83. Polatlı, M., Yorgancıoğlu, A., Aydemir, Ö., Yılmaz Demirci, N., Kırkıl, G., Atış Naycı, S. ve diğerleri. (2013) St. George solunum anketinin Türkçe geçerlilik ve güvenilirliği. Tüberküloz ve Toraks, 61 (2), 81-87 84. Sutcu Cicek H, Akbayrak N. Kroni̇k Obstrükti̇f Akci̇ǧer Hastaligi olan bi̇reylerde solunum egzersi̇zleri̇ni̇n kan gazlari ve solunum fonksiyon testleri̇ne etki̇si̇. Gulhane Med J. 2004;46(1):1–9. 85. Faria AG, Ribeiro MAGO, Marson FAL, Schivinski CIS, Severino SD, Ribeiro JD, et al. Effect of exercise test on pulmonary function of obese adolescents. J Pediatr (Rio J). 2014;90(3):242–9. 86. American Thoracic Society. (1981). Medical Section of the American Lung Association. Pulmonary rehabilitation. Am Rev Respir Dis, 124(5), 663- 666 87. Demirci Üçsular F,Kayık Demir A,Polat G,Güçlü S.KOAH’lı olguların sigara içme özellikleri.2004;(3):107-112 88. Borge CR,Wahl AK,Moum T, Pain and quality of life with chronic obstructive pulmonary disease, Heart Lung.2011;40(3) 90-101. 89. Bentsen S, Christine M, Bruce AC, Vivi LC, Anne H, Holm A,Rustoen T, Distinct pain profiles in patients with chronic obstructive pulmonary disease, Int J Chron Obstruct Pulmon.Dis. 2018;13:801-811. 90. HajGhanbari B, Holsti L, Road JD,Reid D, Pain in people with chronic obstructive pulmonary disease (COPD).University of British Columbia,Canada. 2012 91. Knight DA, Yang I, Ko FWS, Lim TK. (2012). Year in review 2011: Asthma, COPD and airway biology. Respirology, 17, 563- 572 92. HajGhanbari B,Garland S.J.,Road JD.,Reid W.D,Pain and physical performancein people with COPD,University of Biritish Columbia,Canada 2013 93. Mannino DM, Buist AS. (2007). Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 370, 765- 73 94. Smith MD, Chang AT, Seale HE, Walsh JR, Hodges PW. (2010). Balance is impaired in people with chronic obstructive pulmonary disease. Gait & Posture, 31, 456- 460 95. Morais N,Cruz J, Marques A,Posture and mobility of the upper body quadrant and pulmonary function in COPD,Braz J Phys Ther.2016; 20 (4):345-354. 96. Lee A, Zabjek K, Goldstein R, Brooks D, Postural abnormalities in people with chronic obstructive pulmonary disease, Europan Respiratory Journal 2016;48:PA1344 97. Yoshimi K, Ueki J, Seyama K, Takizawa M, Yamaguchi S, Kitahara E, et al. Pulmonary rehabilitation program including respiratory conditioning for chronic obstructive pulmonary disease (COPD): Improved hyperinflation and expiratory flow during tidal breathing. Vol. 4, Journal of Thoracic Disease. 2012. p. 259–64. 98. Kargın N, Marakoğlu K, Sigarayı bırakmanın solunum işlevleri üzerine etkisi, Selçuk Üniversitesi Tıp Fakültesi Aile Hekimliği Anabilim Dalı,Konya, 2015; 19(3):130-135. 99. Durutürk N,(2013)Kronik Obstrüktif Akciğer Hastalığı Olan Hastalarda Bisiklet Ergometresi İle Kalistenik Egzersiz Eğitiminin Karşılaştırılması,Doktora Yeterlilik Tezi,Hacettepe Üniversitesi,Ankara 100. Bodil Bjoernshave, Jens Korsgaard, Chris Jensen CVN. Participation in pulmonary rehabilitation in routine clinical practice. Clin Respir J. 2011; 101. Corhay J-L, Dang DN, Van Cauwenberge H, Louis R. Pulmonary rehabilitation and COPD: providing patients a good environment for optimizing therapy. Vol. 9, International Journal of Chronic Obstructive Pulmonary Disease. 2014. p. 27–39. 102. Akkoca Ö,Karabıyıkoğlu G, Kronik obstruktif akciğer hastalarında diffüzyon kapasitesinin spesifik diffüzyon katsayısının önemi, Ankara Üniversitesi Tıp Fakültesi,Ankara 1996 ; 49 (1): 39-44 103. Morrison NJ, Abboud RT, Ramadan F et al.Comparison of DLCO and pressure-volume curves in detecting emphysema. Am Rev Respir Dis 1989; 139:1179-1187. 104. Knudson RJ, Kaltenbom WT, Knudson DE,et al. The single-breath carbon monoxide diffusing capacity: reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis 1987; 135: 805-811. 105. Troosters T, Gosselink R, Decramer M. (2001). Exercise training in COPD: how to distinguish responders from non-responders. J Cardiopulm Rehabil, 21, 10- 7 106. Nici L. (2000). Mechanisim and measures of exercise intolerance in COPD. Clin Chest Med, 21, 693- 704 107. Singer J, Yelin EH, Katz PP, Sanchez G, Iribarren C, Eisner MD, et al. Respiratory and skeletal muscle strength in COPD: Impact on exercise capacity and lower extremity function. J Cardiopulm Rehabil Prev [Internet]. 2011;31(2):111–9. 108. Bohannon RW. Muscle strength: clinical and prognostic value of hand-grip dynamometry. Curr Opin Clin Nutr Metab Care. 2016;18(5):465–470. 109. Fujimoto K, Kitaguchi Y, Kubo K, Honda T. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology. 2018;11(6):731–740. 110. Lear S, Brozıc A, Myers JN, Ignaszewskı A. (1999). Exercise stres testing. Sports Med, 27(5), 285- 312 111. Kim K, Byun M, Lee W, Cynn H, Kwon O, Yi C. Effects of breathing maneuver and sitting posture on muscle activity in inspiratory accessory muscles in patients with chronic obstructive pulmonary disease. Vol. 7, Multidisciplinary Respiratory Medicine. 2012. p. 9. 112. Antonello N, Valentina M, Bruna G, Maura F-B, Banfi P, Cornelius B. Comparıson Of Effectıveness Of Temporary Posıtıve Expırayory Pressure Versus Oscıllatory Posıtıve Expıratory Pressure In Severe Copd Patıents. Clin Respir J. 2017 Jun; 113. Johnson MA, Polgar J, Weightman D, Appleton D. Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. J Neurol Sci. 1973 Jan;18(1):111–29. 114. Fritz M, Fransen E, Broekhuizen R ve diğerleri. (2005). Limp muscle dysfunction in COPD: Effects of muscle wasting and exercise trainig. Med Sci Sport Exerc, 37, 2- 9 115. Beauchamp MK, Hill K, Goldstein RS, Janaudis-Ferreira T, Brooks D. (2009). Impairments in balance discriminate fallers from non-fallers in COPD. Respiratory Medicine, 103, 1885- 91 116. Man WDC, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004 Jun;59(6):471–6. 117. Mador MJ, Mogri M, Patel A. Contractile fatigue of the quadriceps muscle predicts improvement in exercise performance after pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2014;34(1):54–61. 113. Carbo N, Busquets S, van Royen M, Alvarez B, Lopez-Soriano FJ, Argiles JM. TNF-alpha is involved in activating DNA fragmentation in skeletal muscle. Br J Cancer. 2002 Mar;86(6):1012–6. 114. Jobin J, Maltais F, Doyon JF, LeBlanc P, Simard PM, Simard AA, et al. Chronic obstructive pulmonary disease: capillarity and fiber-type characteristics of skeletal muscle. J Cardiopulm Rehabil. 1998;18(6):432–7. 115. Dentener MA, Creutzberg EC, Schols AM, Mantovani A, van’t Veer C, Buurman WA, et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax. 2001 Sep;56(9):721–6. 116. Aniwidyaningsih W, Varraso R, Cano N, Pison C. Impact of nutritional status on body functioning in chronic obstructive pulmonary disease and how to intervene. Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):435–42. 117. Barnes, P.J., Celli, B.R. (2009) Systemic manifestations and comorbidities of COPD. European Respiratory Journal, 33 (5), 1165-1185. 118. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol [Internet]. 2011;21(9):655–79. Available from: http://www.sciencedirect.com/science/article/pii/S0924977X11001726 119. Pumar MI, Gray CR, Walsh JR, Yang IA, Rolls TA, Ward DL. Anxiety and depression-Important psychological comorbidities of COPD. J Thorac Dis. 2014 Nov;6(11):1615–31. 120. Bratas O, Espnes GA, Rannestad T, Walstad R. Pulmonary rehabilitation reduces depression and enhances health-related quality of life in COPD patients--especially in patients with mild or moderate disease. Chron Respir Dis. 2010;7(4):229–37. 121. Janssen DJA, Spruit MA, Leue C, Gijsen C, Hameleers H, Schols JMGA, et al. Symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. Chron Respir Dis. 2010 Aug;7(3):147–57.   122. Van Ede L, Yzermans CJ, Brouwer HJ. (1999). Prevalence of depression in patients with chronic obstructive pulmonary disease: A systematic review. Thorax, 54, 688- 92 123. Kim HF, Kunik ME, Molinari VA, Hillman SL, Lalani S, Orengo CA, Petersen NJ, Nahas Z. (2000). Goodnight-White S. Functional impairment in COPD patients: The impact of anxiety and depression. Psychosomatics, 41, 465- 71. 124. Schneider C, Jick SS, Bothner U, et al. COPD and the risk of depression.Chest 2010, 137(4) ;341-347 125. Goodwin RD,Lavoie KL, Lemeshow AR,et al.Depression,anxiety and copd:The unexamined role of nicotine dependence.Nicotine Tob Res 2012;14:176-183. 126. Mahler DA, Mackowiak JI. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest. 1995 Jun;107(6):1585–9. 127. Limsuwat C, McClellan R, Amiri HM, Nugent K. Pulmonary rehabilitation improves only some domains of health-related quality of life measured by the Short Form-36 questionnaire. Vol. 9, Annals of Thoracic Medicine. India; 2014. p. 144–8. 128. Sousa Pinto JM, Martin-Nogueras AM, Morano MTAP, Macedo TEPM, Arenillas JIC, Troosters T. Chronic obstructive pulmonary disease patients’ experience with pulmonary rehabilitation: a systematic review of qualitative research. Chron Respir Dis. 2013 Aug;10(3):141–57. 129. İnal D. (1997). Kronik obstruktif akciğer hastalarında ve sağlıklı kişilerde yaşam kalitesinin değerlendirilmesi. Bilim Uzamanlığı Tezi, Hacettepe Üniversitesi, Ankara 130. Carter JD, Patel S, Sultan FL, Thompson ZJ, Margaux H, Sterre A, et al. The recogni on and treatment of vertebral fractures in males with chronic obstruc ve pulmonary disease. Respir Med. 2008;102(8):1165-72. 131. Ciric Z, Stankovic I, Pejcic T, Ris c L, Rancic M, Radovic M, et al. Osteoporosis in pa ents with chronic obstruc ve pulmonary disease. Med Arh. 2012;66(6):385-387. 132. Jørgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of osteoporosis in pa ents with chronic obstruc ve pulmonary disease: a cross sec onal study. Respir Med. 2007;101(1):177-85. 133. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am JMed 2003; 114:10–14. 134. Leech JA, Dulberg C, Kellie S, Pattee L, Gay J. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 1990; 141:68–71. 135. Schlaich C, Minne HW, Bruckner T, Wagner G, Gebest HJ, Grunze M, Ziegler R, Leidig- Bruckner G. Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 1998; 8:261–267. 136. Vrieze A,dE Greef MH,Wijkstra PJ,Wempe JB,Low bone mineral density in COPD patients related to worse lung function,low weight and decreased fat-free mass.Osteoporos Int.2007 Sep;18(9):1197-202. 137. Dennison EM, Dhanwai DK, Shaheen SO, Azagra R, Jameson KA, Sayer AA, ve ark.Is lung function associated with bone mineral density?Results from the hertfordshire cohort study. Arch 2013;8(0):115.tr_TR
dc.identifier.urihttp://hdl.handle.net/11655/6561
dc.description.abstractŞahman Çakır F, An analysis of respiratory function, exercise capacity, quality of life, anxiety, pain, muscle strength and bone mineral density in patients with stable COPD. Hacettepe University, Graduate school of Medical Sciences, Department of Physical Medicine and Rehabilitation, Prosthesis Orthesis and Biomechanics Programme, Master’s Thesis, Ankara, 2019. Chronic Obstructive pulmonary disease is characterized by decreased lung capacity and increased airway resistance (COPD) and causes significant mortality and morbidity. The aim of this study was to examine pulmonary function, exercise capacity, quality of life, anxiety, pain, muscle strength, bone mineral density in patients with stable COPD. The study and control groups aged between 40 and 70 years consisted of 40 clinically in stable COPD patients with GOLD stage I and II and 35 non-COPD individuals, respectively. Before and after the treatment, the patients’ pulmonary function and diffusion capacity were evaluated using a spirometer, pain assessments were performed using Numeric Pain Rating Scale (NPRS). Exercise capacity was evaluated using 6 Minute Walk Test (6MWT), depression levels were assessed using Beck Depression Inventory, anxiety levels were evaluated with Beck Anxiety Inventory, quality of life levels were evaluated using Health Assessment Questionnaire (HAQ) and Short From SF36 Survey, whereas bone mineral density was determined using Bone Mineral Densitometry (BMD). Our findings showed that all parameters of the respiratory function tests (FVC%, FEV1%, FEV1/FVC%, FEF25-75 %) of patients with COPD significantly decreased compared to the control group (p<0.05). The difference between the SMWT of patients with COPD significantly decreased compared to the control group (p0.001). The differences in the Beck Anxiety Scale and the Beck Depression Scale of patients with COPD significantly increased compared to the control group (p0.001, p<0.05, respectively). VAS after 6MWT and VAS at rest patients with COPD significantly increased compared to the control group (p0.001, p<0.05, respectively). The gastrocnemius and abdominal muscle strengths of patients with COPD significantly decreased compared to the control group (p0.05). The difference between Hamstring, Quadriceps and Back Extensors was not significant between the two groups (p0.05). When the BMD was evaluated, there was no statistically significant difference in any of the variables between the COPD and the Control Groups (p0.05). According to our results, in stable COPD patients, pulmonary function, exercise capacity, quality of life and muscle strength decreased, whereas pain level, anxiety and depression level were increased, and contrary to expectations, there was no change in posture and BMD skores.tr_TR
dc.description.tableofcontentsİÇİNDEKİLER ONAY SAYFASI iii YAYIMLAMA VE FİKRİ MÜLKİYET HAKLARI BEYANI iv ETİK BEYAN v TEŞEKKÜR vi ÖZET vii ABSTRACT viii İÇİNDEKİLER ix SİMGELER VE KISALTMALAR xii ŞEKİLLLER xvi TABLOLAR xvii 1. GİRİŞ VE AMAÇ 1 2. GENEL BİLGİLER 4 2.1. Kronik Obstrüktif Akciğer Hastalığı (KOAH) Risk Faktörleri 7 2.2. Kronik Obstrüktif Akciğer Hastalığının Patoloji, Patogenez ve Patofizyolojisi 9 2.3. Kronik Obstrüktif Akciğer Hastalığının Alt Tipleri 11 2.4. Kronik Obstrüktif Akciğer Hastalığının Semptomları ve Bulguları: 12 2.5. Kronik Obstrüktif Akciğer Hastalığında Değerlendirme 14 2.5.1. Fizik Muayene 14 2.5.2. Spirometrik Değerlendirme 15 2.5.3. Fizyoterapi Değerlendirmesi 17 3. BİREYLER VE YÖNTEM 20 3.1. Bireyler 20 3.2. Yöntem 21 3.3. Değerlendirme 21 3.3.1. Demografik Özellikler 22 3.3.2. Sosyodemografik Özellikler 22 3.3.3. Özgeçmiş 22 3.3.4. Alışkanlıklar 22 3.3.5.Ağrının Değerlendirilmesi 22 3.3.6. Postür Değerlendirilmesi 22 3.3.7. Solunum ve Kalp Hızı Değerlendirilmesi 22 3.3.8. Kronik Obstrüktif Akciğer Hastalığı Semptomlarının Değerlendirilmesi 23 3.3.9. Solunum Testlerinin Değerlendirilmesi 24 3.3.10. Egzersiz Kapasitesinin Değerlendirilmesi 26 3.3.11. Kas Kuvvetinin Değerlendirilmesi 26 3.3.12. Anksiyete ve Depresyonun Değerlendirilmesi 26 3.3.13. Yaşam Kalitesinin Değerlendirilmesi 27 3.3.14. Kemik Mineral Yoğunluğu 27 3.4. İstatistiksel Analiz 27 4. BULGULAR 29 4.1. Demografik Özellikler 29 4.2. Sigara Tüketimi 30 4.3. Ağrı 31 4.4. Postür 32 4.5. Solunum Fonksiyon Testleri 32 4.6. Egzersiz Kapasitesi 33 4.7. Kas Kuvveti 34 4.8. Anksiyete- Depresyon 34 4.9. Yaşam Kalitesi 35 4.10. Kemik Mineral Yoğunluğu 36 4.11. Değerlendirme Parametrelerinin Etki Büyüklüklerinin Karşılaştırılması 37 5. TARTIŞMA 38 6. SONUÇLAR VE ÖNERİLER 54 7. KAYNAKLAR 56 8. EKLER Ek 1. Modifiye MRC Dispne Skalası Ek 2. KOAH Değerlendirme Anketi (COPD- Assessement Test=CAT) Ek 3. St.George’s Respiratory Questionnaire (SGRQ) Ek 4. Beck Anksiyete Ölçeği Ek 5. Beck Depresyon Ölçeği Ek 6. Sağlık Değerlendirme Anketi HAQ EK 7. SF-36 Yaşam Kalitesi Ölçeği EK 8. Etik Kurul Formu EK 9. Orjinallik Ekran Çıktısı EK 10. Dijital Makbuz 9. ÖZGEÇMİŞ  tr_TR
dc.publisherSağlık Bilimleri Enstitüsütr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectKOAHtr_TR
dc.titleStabil Durumdaki KOAH Hastalarında Solunum Fonksiyonları, Egzersiz Kapasitesi, Yaşam Kalitesi, Anksiyete İle Birlikte Ağrı, Kas Kuvveti Ve Kemik Mineral Yoğunluğunun İncelenmesitr_TR
dc.typeinfo:eu-repo/semantics/masterThesisen
dc.description.ozetŞahman Çakır F, Stabil durumdaki KOAH hastalarında solunum fonksiyonları, egzersiz kapasitesi, yaşam kalitesi, anksiyete ile birlikte ağrı, kas kuvveti ve kemik mineral yoğunluğunun incelenmesi, Hacettepe Üniversitesi, Sağlık Bilimleri Enstitüsü, Fizik Tedavi ve Rehabilitasyon Anabilim Dalı, Protez Ortez ve Biyomekanik Programı, Yüksek Lisans Tezi, Ankara, 2019. Kronik obstrüktif akciğer hastalığı (KOAH), akciğer kapasitesinde azalma ve hava yolu direncinde artma ile karakterize önemli mortalite ve morbiditeye sebep olan bir hastalıktır. Bu çalışmanın amacı; GOLD evre I ve II olan stabil durumdaki KOAH’lı hastalarda solunum fonksiyonları, egzersiz kapasitesi, yaşam kalitesi, anksiyete ile birlikte ağrı, kas kuvveti ve kemik mineral yoğunluğunun incelenmesidir. Çalışmaya 40-70 yıl yaş aralığında değişen klinik olarak stabil 40 KOAH’lı birey ve aynı yaş grubunda 35 KOAH olmayan birey alınmıştır. KOAH’lı hastaların ve kontrol grubunun değerlendirilmesinde solunum fonksiyonları ve diffüzyon kapasiteleri spirometre ile, ağrı değerlendirmeleri vizüel analog skalası (VAS) ile, her iki grubun egzersiz kapasiteleri 6 Dakika Yürüme Testi (6DYT) ile, depresyon düzeyleri, Beck Depresyon Anketi ile, anksiyete düzeyleri Beck Anksiyete Ölçeği ile, yaşam kalitesi Sağlık Değerlendirme Anketi (HAQ) ve Kısa form SF36 anketleri ile, kemik mineral yoğunlukları ise kemik mineral dansitometrisi (BMD) ile değerlendirilmiştir. Çalışma sonucunda KOAH’lı hastaların solunum fonksiyon test değerleri tüm parametrelerinde (FVC%, FEV1%, FEV1FVC%, FEF25-75%), kontrol grubuna göre azalmıştır.(p0,05) 6DYT sonuçları KOAH grubunda kontrol grubuna göre azalmıştır (p0,001). Beck Anksiyete ve Beck Depresyon ölçeği KOAH grubunda kontrol grubuna göre daha yüksektir (p0,001). 6DYT sonrası ağrı (VAS) ve istirahatte ağrı değerleri KOAH grubunda daha yüksek bulunmuştur (p<0,05). KOAH ve kontrol gruplarının Gastroknemius ve Abdominal kas kuvveti KOAH grubunda kontrol grubuna göre daha düşük bulunmuştur (p<0,05). Hamstring, Kuadriseps ve Sırt Ekstansörler iki grup karşılaştırıldığında benzer bulunmuştur (p0,05). Kemik mineral yoğunluğu da iki grupta benzer bulunmuştur (p0,05). Sonuçlarımıza göre, stabil KOAH hastalarında pulmoner fonksiyonlar, egzersiz kapasitesi, yaşam kalitesi ve kas kuvveti azalırken, ağrı seviyesi, anksiyete ve depresyon düzeyleri artmıştır, postür ve kemik mineral yoğunluğunda ise KOAH grubunda azalması beklenirken, aksine fark görülmemiştir.tr_TR
dc.contributor.departmentFizyoterapi ve Rehabilitasyontr_TR
dc.contributor.authorID10243995tr_TR
dc.embargo.termsAcik erisimtr_TR
dc.embargo.lift2019-04-12T12:36:15Z


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster